Exacerbations Among Patients Receiving Breztri (EROS Study)

Study identifier:D5980R00079

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Exacerbations and Real-World Outcomes Among Chronic Obstructive Pulmonary Disease Patients Receiving Breztri (EROS Study)

Medical condition

Pulmonary Disease

Phase

Phase 4

Healthy volunteers

No

Study drug

BGF

Sex

All

Actual Enrollment

2409

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 01 Oct 2022
Primary Completion Date: 07 Mar 2023
Study Completion Date: 07 Mar 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria